iSBTc 19th Annual Meeting

Annual Meeting Main Page | Award Winners | Download Final Program

| Faculty | Pictures
Presentation Slides & Schedule | Session & Abstract Topics

Some presentations are available for viewing. Please select the icon to view a presentation.

Friday, November 5, 2004
7:55 am - 8:15 am	Welcome Address Steven Hirschfeld, MD, PhD FDA Office of Cellular, Tissue and Gene Therapies
8:15 am - 9:00 am	Keynote Address Design and Selection of Vaccine Adjuvants Carl Alving, MD Walter Reed Army Institute of Research
9:00 am - 11:45 am	Plenary Session: Immune Adjuvants Chair(s) Eli Gilboa, PhD Duke University Medical Center Donald L. Morton, MD John Wayne Cancer Institute
9:00 am - 9:30 am	Immunomodulation of Cellular and Humoral Responses During Active Immunotherapy for Melanoma Donald L. Morton, MD John Wayne Cancer Institute
9:30 am - 10:00 am	Immunological Adjuvants, the Indispensable Third Component Philip O. Livingston, MD Memorial Sloan-Kettering Cancer Center
10:00 am - 10:15 am	Regression of Established Autochthonous Mammary Tumors and Induction of Systemic Anti-Tumor T- and B-Cell Immunity in HER-2/NEU Transgenic Mice after Treatment with IL-12 and GM-CSF-Encapsulated Microspheres Nejat Egilmez, PhD J.G. Brown Cancer Center
10:15 am - 10:30 am	Induction of TH1-Type Immunity and Tumor Protection with a Prostate Specific Antigen DNA Vaccine and pIL-18 Adjuvant Therapy Deborah J. Marshall, PhD Centocor, Inc.
11:00 am - 11:15 am	Adjuvant Effect of Topical Imiquimod Compared to Intradermal GM-CSF on the Cellular Composition of Draining Lymph Nodes Wolfgang M. Wagner, PhD University of Washington
11:15 am - 11:45 am	Therapeutic Vaccination with mRNA Transfected Dendritic Cells Eli Gilboa, PhD Duke University Medical Center
11:45 am - 1:00 pm	Odd Number Poster Presentations/Box Lunches
1:00 pm - 3:00 pm	Plenary Session: Adoptive Immunotherapy Chair(s) Bernard A. Fox, PhD Earle A. Chiles Research Institute Patrick Hwu, MD MD Anderson Cancer Center
1:00 pm - 1:15 pm	Adoptive Immunotherapy of Cancer with Polyclonal Hyperexpanded CD4 and CD8 T Cells Derived from Tumor-Draining Lymph Nodes Gregory E. Plautz, MD Cleveland Clinic Foundation
1:15 pm - 1:30 pm	Therapeutic Efficacy of MUC1-Specific Cytotoxic T Lymphocytes and CD137 Co-Stimulation in a Spontaneous Mammary Cancer Model Pinku Mukherjee, PhD Mayo Clinic Scottsdale
1:30 pm - 2:00 pm	Enhanced Antitumor Effects Using Dendritic Cells to Stimulate Adoptively Transferred T Cells In Vivo Patrick Hwu, MD MD Anderson Cancer Center
2:00 pm - 2:30 pm	Tumor Antigen Immunization of Human Allotransplant Donors in Myeloma Larry Kwak, MD, PhD MD Anderson Cancer Center
2:30 pm - 3:00 pm	Exploiting Lymphopenia to Reboot the Immune Response to Cancer Bernard A. Fox, PhD Earle A. Chiles Research Institute
3:15 pm - 5:30 pm	Concurrent Session I: Cancer Biometrics Review Chair(s) Michael T. Lotze, MD University of Pittsburgh School of Medicine George Coukos, MD, PhD University of Pennsylvania Medical Center
3:15 pm - 3:30 pm	Where�s the Rub � Really Useful Biomarkers in Cancer Michael T. Lotze, MD University of Pittsburgh School of Medicine
3:30 pm - 4:00 pm	Clinical Proteomics: Applications at the Bedside Julia Wulfkuhle, MD Division of Therapeutic Products/CBER/FDA
4:00 pm - 4:30 pm	Bioinformatical Data Reduction Approaches for High Dimensional Data Derived from High Throughput Assays Yu Shyr, MD Vanderbilt University School of Medicine
4:30 pm - 4:45 pm	Flow Cytometric Monitoring of Jak-STAT Signal Transduction Within Melanoma Cells Gregory B. Lesinski, PhD The Ohio State University
4:45 pm - 5:00 pm	Characterizing Complete Responders to IL-2 Using Gene Expression Analysis and Tissue Array Validation in Patients with Metastatic Renal Cell Carcinoma Allan Pantuck, MD University of California Los Angeles
5:00 pm - 5:15 pm	Gene Expression Patterns Associated with Renal Cancer (RCC) Response and Resistance to IL-2-Based Therapy Philip G. Febbo, MD Duke Institute for Genome Science and Policy
5:15 pm - 5:30 pm	Markers from the Tumor Microenvironment. Are They Useful? George Coukos, MD, PhD University of Pennsylvania Medical Center
3:30 pm - 5:15 pm	Concurrent Session II: Dendritic Cells and Vaccines Chair(s) Craig L. Slingluff, Jr., MD University of Virginia Jeffrey S. Weber, MD, PhD University of Southern California Norris Cancer Center
3:30 pm - 3:45 pm	Dacarbacine (DTIC) Versus Vaccination with Autologous Peptide-Pulsed Dendritic Cells (DC) in First-Line Treatment of Patients with Metastatic Melanoma: Results of a Multicenter Prospective Randomized Phase III Study Dirk Schadendorf, MD German Cancer Research Center
3:45 pm - 4:00 pm	Strategies to Augment the Efficacy of Dendritic Cell-Based Vaccines Johannes Vieweg, MD FACS Duke University
4:00 pm - 4:15 pm	Invited Speaker Q&A
4:15 pm - 4:30 pm	Treatment of Metastatic Colorectal Cancer Patients with a Tumor Lysate Pulsed Dendritic Cell Vaccine: A Randomized Evaluation of Ex Vivo CD40L Activation Richard J. Barth, Jr., MD Dartmouth-Hitchcock Medical Center
4:30 pm - 4:45 pm	A Randomized Placebo-Controlled Phase II Study with the Cancer Vaccine IGN101 in Patients with Epithelial Cancers Marc Salzberg Pharma Brains, Ltd.
4:45 pm - 5:00 pm	Vaccination of Patients with Recurrent AML with WT1-Peptide Induces Clinical and Molecular Remissions as Well as Specific Memory and Effector T Cells in Perhipheral Blood and Bone Marrow Anne Letsch, MD Charit� Campus Benjamin Franklin
5:00 pm - 5:15 pm	Multipeptide Vaccines for Melanoma: Strategies for Increasing the Breadth of the T Cell Repertoire Craig L. Slingluff, Jr., MD University of Virginia
Saturday, November 6, 2004
8:15 am - 9:00 am	Keynote Address Regulatory T Cells: Friend or Foe Ethan Shevach, MD National Institutes of Health
9:00 am - 11:45 am	Plenary Session: Mechanisms of Escape/Resistance Chair(s) Thomas Gajewski, MD, PhD University of Chicago Medical School David Munn, MD Medical College of Georgia
9:00 am - 9:15 am	Cross Resistance of Melanoma Cells to Apoptosis Induced by Trail and Chemotherapy Peter Hersey, MD, PhD Newcastle Mater Hospital
9:15 am - 9:30 am	MYCN Regulates CCL2/MCP-1 Production in Neuroblastoma Cells: A Mechanism of Tumor Escape and a Target for Immunotherapy Liping Song, PhD Childrens Hospital Los Angeles
9:30 am - 10:00 am	Mechanisms of Resistance to Anti-Tumor Immunity Downstream from Initial T Cell Priming Thomas Gajewski, MD, PhD University of Chicago Medical School
10:00 am - 10:15 am	Melanoma Gene Expression Profiles To Identify Mechanisms of Tumor Resistance to a Multi-Peptide/IL-12 Vaccine Helena A. Harlin, PhD University of Chicago
10:45 am - 11:15 am	Tryptophan Catabolism and Tumor Immune Evasion David Munn, MD Medical College of Georgia
11:15 am - 11:45 am	Changing Battlefields: Bring Immune Response Into Tumor Site Yang-Xin Fu, MD, PhD University of Chicago
11:45 am - 1:00 pm	Even Number Poster Presentations/Box Lunches
1:00 pm - 2:20 pm	Plenary Session: iSBTc Presidential Session Chair Michael B. Atkins, MD Beth Israel Deaconess Medical Center
1:00 pm - 1:20 pm	Tumor-Infiltrating Dendritic Cell Precursors Recruited by a β-Defensin Contribute to Vasculogenesis Under the Influence of VEGF-A in Ovarian Cancer Jose Ramon Conejo-Garcia, MD, PhD University of Pennsylvania
1:20 pm - 1:40 pm	Imiquimod Treatment In Vivo Induces Massive Skin Recruitment and Activation of Plasmacytoid Dendritic Cells in a Disease-Independent Manner Mirjana Urosevic, MD University Hospital Zurich
1:40 pm - 2:00 pm	CpG in the Immunotherapy of B Cell Lymphoma in an Animal Model Jiali Li, PhD (Presidential Award Winner) Stanford University
2:00 pm - 2:20 pm	Acquisition of Terminal Effector Functions In Vitro Impairs In Vivo Anti- Tumor Efficacy Luca Gattinoni, MD (Presidential Award Winner) National Cancer Institute - Surgery Branch
2:30 pm - 4:00 pm	Concurrent Session I: Poster Presentations 2:30 pm - 3:15 pm Odd Number Poster Session 3:15 pm - 4:00 pm Even Number Poster Session
2:45 pm - 4:15 pm	Concurrent Session II: Cytokines Chair(s) Jared A. Gollob, MD Duke University Medical Center Steven Dubinett, MD University of California Los Angeles Lung Cancer Research Program
2:45 pm - 3:15 pm	Cyclooxygenase-2 Regulates Cytokine Balance and Apoptosis Resistance in Non-Small Cell Lung Cancer Steven Dubinett, MD University of California Los Angeles Lung Cancer Research Program
3:15 am - 3:30 pm	Expression of CXC Chemokines During IL-2 Therapy Correlates with Response in Metastatic Renal Cell Carcinoma Karen Riedl, MD University of California Los Angeles, David Geffen School of Medicine
3:30 pm - 3:45 pm	Grade 4 Thrombocytopenia During Treatment with High-Dose Interleukin-2 Is a Predictor of Response in Melanoma But Not in Renal Cell Cancer Timothy E. Bael, MD Duke University Medical Center
3:45 pm - 4:15 pm	Use of DNA Microarray Analysis to Identify Genes and Signaling Pathways Central to the Anti-Melanoma Effect of Interferon-� Jared A. Gollob, MD Duke University Medical Center
4:00 pm - 5:00 pm	Poster Discussion Session I
4:00 pm - 4:20 pm	Discussion on Dendritic Cells and Vaccines Howard L. Kaufman, MD New York Presbyterian Hospital -Columbia Campus
4:20 pm - 4:35 pm	Discussion on Mechanisms of Escape/Resistance James W. Mier, MD Beth Israel Deaconess Medical Center
4:35 pm - 4:50 pm	Discussion on Adoptive Immunotherapy James W. Young, MD Memorial Sloan-Kettering Cancer Center
4:50 pm - 5:00 pm	General Discussion
4:30 pm - 5:00 pm	Poster Discussion Session II
4:30 pm - 4:45 pm	Discussion on Antibody Therapy George J. Weiner, MD University of Iowa
4:45 pm - 5:00 pm	Discussion on Natural Killer Cells & Innate Immunity Theresa L. Whiteside, PhD University of Pittsburgh Cancer Institute
Sunday, November 7, 2004
8:00 am - 11:00 am	Plenary Session: New Agents in Development - Sponsored by Antigenics Chair(s) Steven J. O�Day, MD John Wayne Cancer Center Gary R. Jones, MD Berlex Laboratories
8:00 am - 8:30 am	Epigenetic Therapy Peter Jones, PhD University of Southern California Norris Comprehensive Cancer Center
8:30 am - 8:45 am	Heat Shock Protein-Based Immunotherapy of Cancer Alem Truneh, PhD Antigenics, Inc.
8:45 am - 9:15 am	Interleukin-21 Elicits Durable T and NK Cytotoxicity: Basic Biology to Clinical Trials Pallavur V. Sivakumar, PhD Zymogenetics, Inc.
9:15 am - 9:30 am	Threshold of Credibility: A New Approach to Product Development for Metastatic Melanoma Therapy Steven Hirschfeld, MD, PhD FDA Office of Cellular, Tissue and Gene Therapies
9:30 am - 9:45 am	T-Cell Independent Activity of Talabostat (PT-100) Against Human Tumor Xenografts in Mice Barry Jones, PhD Point Therapeutics
9:45 am - 10:00 am	AME-133: A Next-Generation Anti-CD20 Engineered for Enhanced Killer Function James B. Breitmeyer, MD, PhD Applied Molecular Evolution, Inc.
10:00 am - 10:15 am	Enhancement of Anti-Tumor Efficacy of Paclitaxel by CpG ODN; TLR9 Agonist in Metastatic Murine Cancer Models Risini D. Weeratna, PhD Coley Pharmaceutical Group
10:15 am - 10:30 am	Therapeutic Efficacy of Gc Protein-Derived Macrophage Activating Factor (GcMAF) for Adenocarcinoma Nobuto Yamamoto, PhD Socrates Institute for Therapeutic Immunology
10:30 am - 10:45 am	A Phase I Trial of Immunocytokine HU14.18-IL2 in Children with Recurrent or Refractory Neuroblastoma and Other GD2 Positive Malignancies: A Study of the Children�s Oncology Group Kaci L. Osenga, MD University of Wisconsin Comprehensive Cancer Center
10:45 am - 11:00 am	Proteasome Inhibition To Maximize the Apoptotic Potential of Cytokine Therapy for Murine Neuroblastoma Tumors Tahira Khan, PhD National Cancer Institute

All presentations are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

iSBTc 19th Annual Meeting

Membership Links

Get Involved